reports
Texas Capital President & Chief Executive Officer Rob C. Holmes Now Se...
Texas Capital President & Chief Executive Officer Rob C. Holmes Now Serves as Chairman of the Board DALLAS, April 15, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced that President & Chief Executive Officer Rob C. Holmes was confirmed as Chairman of the Board of Directors at the conclusion of TCBI’s 2025 Annual Meeting of Stockholders. Holmes, who has served as President & Chief Executive Officer and a Director of the Board since 2021, was to this position by the Board of Directors in January 2025. Bob Stalling...
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMR...
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the Ne...
Texas Capital Bancshares, Inc. Announces Date for Q1 2025 Operating Re...
Texas Capital Bancshares, Inc. Announces Date for Q1 2025 Operating Results DALLAS, April 03, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the first quarter of 2025 before market on Thursday, April 17, 2025. Executive management will host a conference call and webcast to discuss first quarter 2025 operating results on Thursday, April 17, 2025, at 9:00 a.m. EDT. Participants may pre-register for the call by visiting and will receive a unique PIN number to ...
NBT Bancorp Inc. Announces Date of First Quarter Conference Call
NBT Bancorp Inc. Announces Date of First Quarter Conference Call NORWICH, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- NBT Bancorp Inc. (“NBT” or the “Company”) (NASDAQ: NBTB) will release details of its financial results for the first quarter 2025 on Thursday, April 24, 2025, following the market close. The Company will host a conference call at 10:00 a.m. (Eastern) Friday, April 25, 2025, to review these results. The audio webcast link, along with the corresponding presentation slides, will be available on the Company’s Event Calendar page at prior to the beginning of the conference ca...
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinic...
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range finding scheduled for completion H2 2026 NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obes...
Community West Bank Appoints Hinson M. Thomas as Chief Credit Officer
FRESNO, Calif.--(BUSINESS WIRE)-- James J. Kim, President and CEO of Community West Bank (the Bank), announced today the appointment of Hinson M. Thomas as Executive Vice President and Chief Credit Officer (CCO) for the Bank, effective March 17, 2025. Thomas brings over 30 years of experience in credit risk management, commercial banking and lending. Most recently, he served as EVP, Chief Credit Officer for a California-based community bank. A respected financial services industry leader, Thomas is highly regarded for his ability to foster strong teams and nurture commercial, small business a...
CVB Financial Corp. Announces 142nd Consecutive Quarterly Cash Dividen...
CVB Financial Corp. Announces 142nd Consecutive Quarterly Cash Dividend Ontario, CA, March 19, 2025 (GLOBE NEWSWIRE) -- CVB Financial Corp. (NASDAQ: CVBF) (the “Company”) announced a twenty cent ($0.20) per share cash dividend with respect to the first quarter of 2025. This dividend was approved at the Company’s regularly scheduled Board of Directors meeting held on March 19, 2025. The quarterly dividend will be payable on or about April 16, 2025 to shareholders of record as of April 2, 2025. “We are pleased to announce our 142nd consecutive quarterly cash dividend paid to our shar...
- Jonathan Moreland
AAON AAON INC.
TTSH TILE SHOP HOLDINGS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
I3N CHART INDUSTRIES INC.
CDXS CODEXIS
APLE APPLE HOSPITALITY REIT INC
TDW TIDEWATER INC
RC GRUPO RADIO CENTRO S.A.B. DE C.V.
ONEW ONEWATER MARINE
CMTG CLAROS MORTGAGE TRUST
CLVT INC.
VSCO CLARIVATE PLC
MCVT VICTORIA'S SECRET & CO
ECAT MILL CITY VENTURES III LTD
SBGI BLACKROCK ESG CAP ALLOCATION TR
DK SINCLAIR INC
CUBA DELEK US HOLDINGS
VG INC.
FDBC THE HERZFELD CARIBBEAN BASIN FUND
INC.
VENTURE GLOBAL INC.
FIDELITY D & D BANCORP INC
- Wedbush Research
MELI MERCADOLIBRE INC.
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
SE SEA ADS
AMZN AMAZON.COM INC.
RCKT ROCKET PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
SRRK SCHOLAR ROCK HOLDING CORPORATION
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
ASO ACADEMY SPORTS AND OUTDOORS
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
HOWL WEREWOLF THERAPEUTICS INC
YOU CLEAR SECURE INC
EWTX EDGEWISE THERAPEUTICS INC
RUM RUMBLE INC
SLDB SOLID BIOSCIENCES INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
CART MAPLEBEAR INC.
TRML TOURMALINE BIO INC
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
- Ritika Das
- Robert Driscoll
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provi...
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701 to treat metastatic cervical cancerCRB 913 SAD/MAD obesity study expected to start in March 2025$149m of cash & investments as of December 31,2024 and cash runway expected through Q3 2027 NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a d...
Catalyst Pharmaceuticals Inc: 2 directors
Two Directors at Catalyst Pharmaceuticals Inc sold after exercising options/sold 93,398 shares at between 22.890USD and 22.976USD. The significance rating of the trade was 91/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trad...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
S&P 500 and Nasdaq 100 Testing Initial Support In last week's 2/25/25 Compass, we discussed our expectation for near-term downside as the S&P 500 and Nasdaq 100 (QQQ) displayed several bearish short-term developments. We also said it likely means at least another 2-4 weeks of consolidation, and that if the S&P 500 remains below 6100 and 6150 resistances, do not be surprised if there is a test of the bottom of the range at either 5770-5850 or 5600-5670, where we would be buyers (though we need 5...
TRV TRAVELERS COMPANIES INC.
AFL AFLAC INCORPORATED
PPL PPL CORPORATION
PFG PRINCIPAL FINANCIAL GROUP INC.
NI NISOURCE INC
NFG NATIONAL FUEL GAS COMPANY
MKL MARKEL CORPORATION
MFC. MANULIFE FINANCIAL CORPORATION
EXC EXELON CORPORATION
ERIE ERIE INDEMNITY COMPANY CLASS A
EQT EQT CORPORATION
ED CONSOLIDATED EDISON INC.
CPK CHESAPEAKE UTILITIES CORPORATION
CB CHUBB LIMITED
ALL ALLSTATE CORPORATION
FNF FIDELITY NATIONAL FINANCIAL INC. - FNF GROUP
MET METLIFE INC.
BRK.B BERKSHIRE HATHAWAY INC. CLASS B
SLF SALAFIN
CNA CNA FINANCIAL CORPORATION
UGI UGI CORPORATION
NJR NEW JERSEY RESOURCES CORPORATION
PRU2 PRUDENTIAL PLC
CINF CI GLOBAL INFRASTRUCTURE PRIVATE POOL
EQH EQUITABLE HOLDINGS INC.
CRBG COREBRIDGE FINANCIAL INC.
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Gl...
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 27th Annual Global Hea...
Oak Valley Community Bank Announces Commercial Credit Officer Hiring
Oak Valley Community Bank Announces Commercial Credit Officer Hiring OAKDALE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oak Valley Community Bank, a wholly-owned subsidiary of Oak Valley Bancorp (NASDAQ: OVLY), announced that Jean Turpen has joined the bank as Vice President, Commercial Credit Officer. She is based out of the Roseville Office located at 1478 Stone Point Drive. Turpen has 21 years of banking experience and a distinguished career in the banking industry, having held various leadership positions in commercial credit and lending. Her understanding of commercial lending, cred...
Paysign to Host Fourth Quarter and Full Year 2024 Earnings Call
HENDERSON, Nev.--(BUSINESS WIRE)-- Paysign, Inc. (NASDAQ: ), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, will discuss fourth quarter and full year 2024 earnings at 5:00 p.m. ET on Tuesday, March 25, 2025. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Replay: Dial-in: 877.660.6853 or +1.201.612.7415 Conference ID: 13752001 The replay will be available until June 25, 2025. To register as a financial professional in ord...
Markel Group Inc: 2 directors
A director at Markel Group Inc sold 2,200 shares at 1,864.760USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2...
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE® Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth Full Year 2025 Total Revenues Expec...
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in the following upcoming investor conferences. B. Riley Securities Precision Oncology & Radiopharma Investor ConferenceFormat: Panel and one-on-one investor meetingsPanel Title: Unlocking the Full Potential of Nectin-4 Targeting TherapiesDate: February 28, 2025Time: 8:00 a.m. ET TD Cowen 45th An...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.